Inflammatory bowel disease and Parkinson's disease are chronic progressive disorders that
mainly affect different organs: the gut and brain, respectively. Accumulating evidence has …

A major challenge in Parkinson disease (PD) will be to turn an emerging and expanding
pipeline of novel disease-modifying candidate compounds into therapeutics. Novel targets …

Background Parkinson's disease (PD) presently is conceptualized as a protein aggregation
disease in which pathology involves both the enteric and the central nervous system …

Parkinson's disease is the second most common neurodegenerative disorder after
Alzheimer's disease and is estimated to affect approximately 1–4% of individuals aged over …

Parkinson's disease (PD) is pathologically characterized by the presence of intraneuronal
inclusions, termed Lewy bodies and Lewy neurites, whose main component is alpha …

Neuromelanin, a dark brown intracellular pigment, has long been associated with
Parkinson's disease (PD). In PD, neuromelanin‐containing neurons preferentially …

Previous studies that have investigated the potential of in vivo abnormal α‐synuclein
deposits as a pathological biomarker for PD included few participants and reported different …

Parkinson's disease (PD) is a common neurodegenerative disorder arising from an interplay
between genetic and environmental risk factors. Studies have suggested that the …

Lewy bodies and neurites, the pathological signatures found in the central nervous system
of Parkinson's disease (PD) patients, are primarily composed of aggregated alpha-synuclein …

In Parkinson's disease (PD), neuronal alpha‐synuclein aggregates are distributed
throughout the nervous system, including the brain, spinal cord, sympathetic ganglia …